Clinical use of biologics in vasculitis syndromes

References

• FalkRJGrossWLGuillevinLGranulomatosis with polyangiitis (Wegener’s): an alternative name for Wegener’s granulomatosisArthritis Rheum201163486386421374588
   PubMed Web of Science ®Google Scholar
• FriesJFHunderGGBlochDAThe American College of Rheumatology 1990 criteria for the classification of vasculitis. SummaryArthritis Rheum1990338113511362202312
   PubMed Web of Science ®Google Scholar
• JennetteJCFalkRJAndrassyKNomenclature of systemic vasculitides. Proposal of an international consensus conferenceArthritis Rheum19943721871928129773
   PubMed Web of Science ®Google Scholar
• CutoloMMontecuccoCMCavagnaLSerum cytokines and steroidal hormones in polymyalgia rheumatica and elderly-onset rheumatoid arthritisAnn Rheum Dis200665111438144316644782
   PubMed Web of Science ®Google Scholar
• Hernandez-RodriguezJGarcia-MartinezACasademontJA strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritisArthritis Rheum2002471293511932875
   PubMed Web of Science ®Google Scholar
• AikawaNEPereiraRMLageLBonfaECarvalhoJFAnti-TNF therapy for polymyalgia rheumatica: report of 99 cases and review of the literatureClin Rheumatol201231357557922234490
   PubMed Web of Science ®Google Scholar
• BejeranoCBlancoRGonzalez-VelaCPolymyalgia rheumatica as presenting manifestation of vasculitis involving the lower extremities in a patient with ulcerative colitisClin Exp Rheumatol2012301 Suppl 70S110S11322640654
   PubMed Web of Science ®Google Scholar
• BejeranoCBlancoRGonzalez-VelaCAgueroRCarrilJMGonzalez-GayMARefractory polymyalgia rheumatica as presenting manifestation of large-vessel vasculitis associated to sarcoidosis. Successful response to adalimumabClin Exp Rheumatol2012301 Suppl 70S94S9722410180
   PubMed Web of Science ®Google Scholar
• ComarmondCPlaisierEDahanKAnti TNF-alpha in refractory Takayasu’s arteritis: cases series and review of the literatureAutoimmun Rev201211967868422155781
   PubMed Web of Science ®Google Scholar
• OsmanMAaronSNogaMYacyshynETakayasu’s arteritis progression on anti-TNF biologics: a case seriesClin Rheumatol201130570370621221688
   PubMed Web of Science ®Google Scholar
• OishiTFujiedaMShiraishiTInfliximab treatment for refractory Kawasaki disease with coronary artery aneurysmCirc J200872585085218441471
   PubMed Web of Science ®Google Scholar
• BurnsJCMasonWHHaugerSBInfliximab treatment for refractory Kawasaki syndromeJ Pediatr2005146566266715870671
   PubMed Web of Science ®Google Scholar
• HiranoTYasukawaKHaradaHComplementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulinNature1986324609273763491322
   PubMed Web of Science ®Google Scholar
• BettelliECarrierYGaoWReciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cellsNature2006441709023523816648838
   PubMed Web of Science ®Google Scholar
• NemethERiveraSGabayanVIL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidinJ Clin Invest200411391271127615124018
   PubMed Web of Science ®Google Scholar
• SardellaGMarianiPD’AlessandroMEarly elevation of interleukin-1beta and interleukin-6 levels after bare or drug-eluting stent implantation in patients with stable anginaThromb Res2006117665966416005497
   PubMed Web of Science ®Google Scholar
• EmilieDLiozonECrevonMCProduction of interleukin 6 by granulomas of giant cell arteritisHum Immunol199439117248181959
   PubMed Web of Science ®Google Scholar
• LecronJCRoblotPChevalierSHigh circulating leukaemia inhibitory factor (LIF) in patients with giant cell arteritis: independent regulation of LIF and IL-6 under corticosteroid therapyClin Exp Immunol199392123268096803
   PubMed Web of Science ®Google Scholar
• RocheNEFulbrightJWWagnerADHunderGGGoronzyJJWeyandCMCorrelation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritisArthritis Rheum1993369128612948216422
   PubMed Web of Science ®Google Scholar
• CorrigallVMDolanALDasguptaBPanayiGSThe sequential analysis of T lymphocyte subsets and interleukin-6 in polymyalgia rheumatica patients as predictors of disease remission and steroid withdrawalBr J Rheumatol19973699769809376994
   PubMedGoogle Scholar
• UddhammarASundqvistKGEllisBRantapaa-DahlqvistSCytokines and adhesion molecules in patients with polymyalgia rheumaticaBr J Rheumatol19983777667699714354
   PubMedGoogle Scholar
• StraubRHGluckTCutoloMThe adrenal steroid status in relation to inflammatory cytokines (interleukin-6 and tumour necrosis factor) in polymyalgia rheumaticaRheumatology (Oxford)200039662463110888707
   PubMed Web of Science ®Google Scholar
• CutoloMStraubRHFoppianiLAdrenal gland hypofunction in active polymyalgia rheumatica. Effect of glucocorticoid treatment on adrenal hormones and interleukin 6J Rheumatol200229474875611950017
   PubMed Web of Science ®Google Scholar
• RoblotPMorelFLelievreEGascanHWijdenesJLecronJCSerum cytokine and cytokine receptor levels in patients with giant cell arteritis during corticotherapyJ Rheumatol19962324084108882065
   PubMed Web of Science ®Google Scholar
• NishimotoNNakaharaHYoshio-HoshinoNMimaTSuccessful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibodyArthritis Rheum20085841197120018383395
   PubMed Web of Science ®Google Scholar
• UnizonySArias-UrdanetaLMiloslavskyETocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, takayasu arteritis) and polymyalgia rheumaticaArthritis Care Res (Hoboken) Epub 2012 Jun 5.
   Web of Science ®Google Scholar
• BredemeierMRochaCMBarbosaMVPitrezEHOne-year clinical and radiological evolution of a patient with refractory Takayasu’s arteritis under treatment with tocilizumabClin Exp Rheumatol2012301 Suppl 70S98S10022410201
   PubMed Web of Science ®Google Scholar
• SalvaraniCMagnaniLCatanosoMGRescue treatment with tocilizumab for Takayasu arteritis resistant to TNF-alpha blockersClin Exp Rheumatol2012301 Suppl 70S90S9322410150
   PubMed Web of Science ®Google Scholar
• ChristidisDJainSDas GuptaBSuccessful use of tocilizumab in polymyalgic onset biopsy positive GCA with large vessel involvementBMJ Case Rep201110.1136/bcr.04.2011.4135
   Google Scholar
• HagiharaKKawaseITanakaTKishimotoTTocilizumab ameliorates clinical symptoms in polymyalgia rheumaticaJ Rheumatol20103751075107620439532
   PubMed Web of Science ®Google Scholar
• Grillo-LopezAJRituximab: an insider’s historical perspectiveSemin Oncol2000276 Suppl 12S9S16
   PubMed Web of Science ®Google Scholar
• EinfeldDABrownJPValentineMAClarkEALedbetterJAMolecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domainsEMBO J1988737117172456210
   PubMed Web of Science ®Google Scholar
• DemidemALamTAlasSHariharanKHannaNBonavidaBChimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugsCancer Biother Radiopharm199712317718610851464
   PubMed Web of Science ®Google Scholar
• GolayJZaffaroniLVaccariTBiologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysisBlood200095123900390810845926
   PubMed Web of Science ®Google Scholar
• ShanDLedbetterJAPressOWSignaling events involved in anti-CD20-induced apoptosis of malignant human B cellsCancer Immunol Immunother2000481267368310752475
   PubMed Web of Science ®Google Scholar
• JohnsonPGlennieMThe mechanisms of action of rituximab in the elimination of tumor cellsSemin Oncol2003301 Suppl 2S3S8
   PubMed Web of Science ®Google Scholar
• UchidaJHamaguchiYOliverJAThe innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapyJ Exp Med2004199121659166915210744
   PubMed Web of Science ®Google Scholar
• AnolikJHBarnardJCappioneARituximab improves peripheral B cell abnormalities in human systemic lupus erythematosusArthritis Rheum200450113580359015529346
   PubMed Web of Science ®Google Scholar
• LiuCYChandrasekarPHMasoodASchifferCAAdherence to hepatitis B screening and prophylactic lamivudine for prevention of rituximab-associated hepatitis B reactivationJ Oncol Pharm Pract Epub 2012 May 25.
   Google Scholar
• SagnelliEPisaturoMSagnelliCCoppolaNRituximab-based treatment, HCV replication, and hepatic flaresClin Dev Immunol Epub 2012 Aug 5.
   Google Scholar
• HoyerBFMumtazIMLoddenkemperKTakayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximabAnn Rheum Dis2012711757921953334
   PubMed Web of Science ®Google Scholar
• SauvagetEBonelloBDavidMChabrolBDubusJCBosdureEResistant Kawasaki disease treated with anti-CD20J Pediatr2012160587587622341587
   PubMed Web of Science ®Google Scholar
• RibeiroECressendTDuffauPRituximab Efficacy during a refractory polyarteritis nodosa flareCase Report Med2009200973829320300599
   PubMedGoogle Scholar
• NeelAMasseauAHervierBLife-threatening hepatitis C virus-associated polyarteritis nodosa successfully treated by rituximabJ Clin Rheumatol201117843944122089995
   PubMed Web of Science ®Google Scholar
• SilvaFSeoPSchroederDRSolid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s): long-term followup of a multicenter longitudinal cohortArthritis Rheum20116382495250321484770
   PubMed Web of Science ®Google Scholar
• FranceschiniDDel PortoPPiconeseSPolyfunctional type-1, -2, and -17 CD8(+) T cell responses to apoptotic self-antigens correlate with the chronic evolution of hepatitis C virus infectionPLoS Pathog201286e100275922737070
   PubMed Web of Science ®Google Scholar
• VauloupCKrzysiekRGreangeot-KerosLEffects of tumor necrosis factor antagonist treatment on hepatitis C-related immunological abnormalitiesEur Cytokine Netw200617429029317353164
   PubMed Web of Science ®Google Scholar
• SpecksUFervenzaFCMcDonaldTJHoganMCResponse of Wegener’s granulomatosis to anti-CD20 chimeric monoclonal antibody therapyArthritis Rheum200144122836284011762944
   PubMed Web of Science ®Google Scholar
• KallenbachMDuanHRingTRituximab induced remission in a patient with Wegener’s granulomatosisNephron Clin Pract Epub2005993c92c9615665552
   PubMedGoogle Scholar
• ErikssonPNine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximabJ Intern Med2005257654054815910558
   PubMed Web of Science ®Google Scholar
• HermleTGoestemeyerAKSwenyPBurnsASuccessful therapeutic use of rituximab in refractory Wegener’s granulomatosis after renal transplantationClin Nephrol200768532232618044265
   PubMed Web of Science ®Google Scholar
• GadolaSDGrossWLVasculitis in 2011: the renaissance of granulomatous inflammation in AAVNat Rev Rheumatol201282747622231230
   PubMed Web of Science ®Google Scholar
• Roubaud-BaudronCPagnouxCMeaux-RuaultNRituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitisJ Rheumatol201239112513022089465
   PubMed Web of Science ®Google Scholar
• Cartin-CebaRFervenzaFCSpecksUTreatment of antineutrophil cytoplasmic antibody-associated vasculitis with rituximabCurr Opin Rheumatol2012241152322089095
   PubMed Web of Science ®Google Scholar
• Cartin-CebaRGolbinJMKeoghKARituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener’s): a single-center ten-year experienceArthritis Rheum Epub 2012 Jun 21.
   Google Scholar
• Cartin-CebaRKeoghKASpecksUSethiSFervenzaFCRituximab for the treatment of Churg-Strauss syndrome with renal involvementNephrol Dial Transplant20112692865287121325353
   PubMed Web of Science ®Google Scholar
• QuartuccioLSoardoGRomanoGRituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroidsRheumatology (Oxford)200645784284616418196
   PubMed Web of Science ®Google Scholar
• ZajaFDe VitaSMazzaroCEfficacy and safety of rituximab in type II mixed cryoglobulinemiaBlood2003101103827383412560225
   PubMed Web of Science ®Google Scholar
• De VitaSQuartuccioLIsolaMA randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitisArthritis Rheum201264384385322147661
   PubMed Web of Science ®Google Scholar
• FerriCCacoubPMazzaroCTreatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literatureAutoimmun Rev2011111485521821153
   PubMed Web of Science ®Google Scholar
• Cordero-ComaMSalomDDiaz-LlopisMLopez-PratsMJCallejaSGolimumab for uveitisOphthalmology201111891892189421889663
   PubMed Web of Science ®Google Scholar
• ParekhKChingDRahmanMUStampLKOnset of Wegener’s granulomatosis during therapy with golimumab for rheumatoid arthritis: a rare adverse event?Rheumatology (Oxford)20104991785178720403913
   PubMed Web of Science ®Google Scholar
• FujiiWKohnoMIshinoHThe rapid efficacy of abatacept in a patient with rheumatoid vasculitisMod Rheumatol201222463063422124545
   PubMed Web of Science ®Google Scholar
• SteinerKMoosigFCsernokEIncreased expression of CTLA-4 (CD152) by T and B lymphocytes in Wegener’s granulomatosisClin Exp Immunol2001126114315011678911
   PubMed Web of Science ®Google Scholar
• GiscombeRWangXHuangDLefvertAKCoding sequence 1 and promoter single nucleotide polymorphisms in the CTLA-4 gene in Wegener’s granulomatosisJ Rheumatol200229595095312022356
   PubMed Web of Science ®Google Scholar
• HuhJRLittmanDRSmall molecule inhibitors of RORgammat: targeting Th17 cells and other applicationsEur J Immunol20124292232223722949321
   PubMed Web of Science ®Google Scholar
• SchabertVFWatsonCGandraSRGoodmanSFoxKMHarrisonDJAnnual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United StatesJ Med Econ201215226427522115327
   PubMedGoogle Scholar